James Lowery Kennedy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6574636/publications.pdf

Version: 2024-02-01

659 papers 48,993 citations

89 h-index 192 g-index

715 all docs

715 docs citations

715 times ranked

44534 citing authors

#	Article	IF	CITATIONS
1	Negative emotionality as a candidate mediating mechanism linking prenatal maternal mood problems and offspring internalizing behaviour. Development and Psychopathology, 2023, 35, 604-618.	1.4	2
2	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	0.7	61
3	Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. American Journal of Geriatric Psychiatry, 2022, 30, 54-64.	0.6	12
4	Mitochondria's role in sleep: Novel insights from sleep deprivation and restriction studies. World Journal of Biological Psychiatry, 2022, 23, 1-13.	1.3	10
5	Neurostructural correlates of <i>BDNF</i> rs6265 genotype in youth bipolar disorder. Bipolar Disorders, 2022, 24, 185-194.	1.1	3
6	Antioxidative Defense Genes and Brain Structure in Youth Bipolar Disorder. International Journal of Neuropsychopharmacology, 2022, 25, 89-98.	1.0	6
7	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	1.0	31
8	Common Genetic Variation and Age of Onset of Anorexia Nervosa. Biological Psychiatry Global Open Science, 2022, 2, 368-378.	1.0	10
9	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	0.7	114
10	Inflammatory markers, brain-derived neurotrophic factor, and the symptomatic course of adolescent bipolar disorder: A prospective repeated-measures study. Brain, Behavior, and Immunity, 2022, 100, 278-286.	2.0	12
11	Association of the MAOA-uVNTR polymorphism with psychopathic traits may change from childhood to adolescence. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1517-1521.	1.8	2
12	COMT Val/Met and Psychopathic Traits in Children and Adolescents: A Systematic Review and New Evidence of a Developmental Trajectory toward Psychopathy. International Journal of Molecular Sciences, 2022, 23, 1782.	1.8	4
13	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Translational Psychiatry, 2022, 12, 101.	2.4	17
14	Examining the role of mitochondrial genetic variation in nicotine dependence. Psychiatry Research, 2022, 310, 114452.	1.7	0
15	P468. Youth Externalizing Behaviour and COMT Val158Met: Evidence of Developmental Change From the Adolescent Brain Cognitive Development (ABCD) European Subsample. Biological Psychiatry, 2022, 91, S278.	0.7	0
16	P118. Preliminary Study of Heart Rate Variability Association With Target Anxiety Genes Across Europeans and East Asians. Biological Psychiatry, 2022, 91, S135.	0.7	0
17	P258. Epigenome-Wide Association Study of Improvement in Depressive Symptoms Across Psychiatric Disorders. Biological Psychiatry, 2022, 91, S192.	0.7	0
18	Schizophreniaâ€associated gene dysbindinâ€1 and tardive dyskinesia. Drug Development Research, 2021, 82, 678-684.	1.4	5

#	Article	IF	Citations
19	Older molecular brain age in severe mental illness. Molecular Psychiatry, 2021, 26, 3646-3656.	4.1	23
20	Maternal Prenatal Mood, Pregnancy-Specific Worries, and Early Child Psychopathology: Findings From the DREAM BIG Consortium. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 186-197.	0.3	40
21	Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [Fâ€18]FEPPA. Addiction Biology, 2021, 26, e12876.	1.4	10
22	Shared genetic risk between eating disorder―and substanceâ€use―elated phenotypes: Evidence from genomeâ€wide association studies. Addiction Biology, 2021, 26, e12880.	1.4	28
23	Neurostructural phenotypes of CACNA1C rs1006737 in adolescents with bipolar disorder and healthy controls. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110071.	2.5	5
24	Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. Journal of Psychopharmacology, 2021, 35, 31-39.	2.0	5
25	An association of Myelin Oligodendrocyte Glycoprotein (MOG) gene variants with white matter volume in pediatric obsessive-compulsive disorder. Psychiatry Research - Neuroimaging, 2021, 307, 111231.	0.9	7
26	Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. Translational Psychiatry, 2021, 11, 91.	2.4	23
27	Dopamine D4 receptor gene polymorphism (DRD4 VNTR) moderates real-world behavioural response to the food retail environment in children. BMC Public Health, 2021, 21, 145.	1.2	7
28	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Translational Psychiatry, 2021, 11, 127.	2.4	22
29	Genome-wide association study of suicidal behaviour severity in mood disorders. World Journal of Biological Psychiatry, 2021, 22, 1-19.	1.3	3
30	HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational Psychiatry, 2021, 11, 214.	2.4	12
31	A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. Biological Psychiatry, 2021, 90, 611-620.	0.7	103
32	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	9.4	629
33	Examining the Genetics of Nicotine Dependence: A Focus on Mitochondrial Genes. Biological Psychiatry, 2021, 89, S136.	0.7	1
34	Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. Schizophrenia Research, 2021, 232, 112-124.	1.1	28
35	Melatonin $\hat{a} \in \mathbb{R}^{m}$ s neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. Translational Psychiatry, 2021, 11, 339.	2.4	42
36	Structural neuroimaging phenotypes of a novel multi-gene risk score in youth bipolar disorder. Journal of Affective Disorders, 2021, 289, 135-143.	2.0	1

#	Article	IF	CITATIONS
37	Supporting pharmacogenetic-guided opioid prescriptions for post-operative pain: The design, protocol and preliminary results of the OTP study. Journal of Psychiatric Research, 2021, 138, 24-33.	1.5	1
38	Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology. Biological Psychiatry, 2021, 90, 652-660.	0.7	12
39	Preliminary insights into the genetic architecture of postpartum depressive symptom severity using polygenic risk scores. Personalized Medicine in Psychiatry, 2021, 27-28, 100081.	0.1	2
40	Increased levels of circulating cell-free mtDNA in plasma of late life depression subjects. Journal of Psychiatric Research, 2021, 139, 25-29.	1.5	18
41	The Interplay Between Prenatal Adversity, Offspring Dopaminergic Genes, and Early Parenting on Toddler Attentional Function. Frontiers in Behavioral Neuroscience, 2021, 15, 701971.	1.0	1
42	Evidence for association of vasopressin receptor 1A promoter region repeat with childhood onset aggression. Journal of Psychiatric Research, 2021, 140, 522-528.	1.5	7
43	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	1.7	20
44	Melatonin as an Add-On Treatment of COVID-19 Infection: Current Status. Diseases (Basel,) Tj ETQq0 0 0 rgBT /	Overlock I	10 Tf 50 462 1
45	Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 2021, 54, 5-17.	1.7	96
46	Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis. Translational Psychiatry, 2021, 11, 509.	2.4	27
47	Potential Genetic Overlap Between Insomnia and Sleep Symptoms in Major Depressive Disorder: A Polygenic Risk Score Analysis. Frontiers in Psychiatry, 2021, 12, 734077.	1.3	2
48	A potential paradigm shift in opioid crisis management: The role of pharmacogenomics. World Journal of Biological Psychiatry, 2021, , 1-13.	1.3	1
49	Circadian genes in major depressive disorder. World Journal of Biological Psychiatry, 2020, 21, 80-90.	1.3	17
50	Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Molecular Psychiatry, 2020, 25, 2455-2467.	4.1	82
51	The complement system in schizophrenia: where are we now and what's next?. Molecular Psychiatry, 2020, 25, 114-130.	4.1	96
52	Proof-of-concept study of a multi-gene risk score in adolescent bipolar disorder. Journal of Affective Disorders, 2020, 262, 211-222.	2.0	10
53	The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. Biological Psychiatry, 2020, 88, 169-184.	0.7	137
54	Preliminary study of structural magnetic resonance imaging phenotypes related to genetic variation in Interleukin- $1\hat{l}^2$ rs16944 in adolescents with Bipolar Disorder. Journal of Psychiatric Research, 2020, 122, 33-41.	1.5	12

#	Article	IF	CITATIONS
55	Predicting risk of suicidal ideation in youth using a multigene panel for impulsive aggression. Psychiatry Research, 2020, 285, 112726.	1.7	14
56	De Novo Damaging DNA Coding Mutations Are Associated With Obsessive-Compulsive Disorder and Overlap With Tourette's Disorder and Autism. Biological Psychiatry, 2020, 87, 1035-1044.	0.7	59
57	Genetics of human startle reactivity: A systematic review to acquire targets for an anxiety endophenotype. World Journal of Biological Psychiatry, 2020, 22, 1-29.	1.3	2
58	Liver enzyme <i>CYP2D6</i> gene and tardive dyskinesia. Pharmacogenomics, 2020, 21, 1065-1072.	0.6	4
59	Regulation of melanocortin-4-receptor (MC4R) expression by SNP rs17066842 is dependent on glucose concentration. European Neuropsychopharmacology, 2020, 37, 39-48.	0.3	3
60	The pharmacogenetics of opioid treatment for pain management. Journal of Psychopharmacology, 2020, 34, 1200-1209.	2.0	10
61	Antidepressant-Associated Mania in Bipolar Disorder: A Review and Meta-analysis of Potential Clinical and Genetic Risk Factors. Journal of Clinical Psychopharmacology, 2020, 40, 180-185.	0.7	17
62	OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial. Alcoholism: Clinical and Experimental Research, 2020, 44, 983-991.	1.4	5
63	Overlapping mechanisms linking insulin resistance with cognition and neuroprogression in bipolar disorder. Neuroscience and Biobehavioral Reviews, 2020, 111, 125-134.	2.9	18
64	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109867.	2. 5	8
65	Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109952.	2.5	8
66	The effect of polymorphisms in startle-related genes on anxiety symptom severity. Journal of Psychiatric Research, 2020, 125, 144-151.	1.5	8
67	A Behavioral Genetic Model of the Mechanisms Underlying the Link Between Obesity and Symptoms of ADHD. Journal of Attention Disorders, 2020, 24, 1425-1436.	1.5	30
68	Integrating genetic variation with DNA methylation at SKA2 rs7208505 in analyses of obsessive-compulsive disorder disease risk and symptom severity. Personalized Medicine in Psychiatry, 2020, 21-22, 100058.	0.1	1
69	Enrichment of pathogenic variants in genes associated with inborn errors of metabolism in psychiatric populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 46-54.	1.1	10
70	S79. Predicting Venlafaxine Remission in Late-Life Depression Using Genome-Wide and Clinical Data. Biological Psychiatry, 2019, 85, S327-S328.	0.7	O
71	Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nature Genetics, 2019, 51, 1207-1214.	9.4	641
72	Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics. Journal of Psychiatric Research, 2019, 119, 33-47.	1.5	19

#	Article	IF	CITATIONS
73	F141IDENTIFICATION OF PERIPHERAL BIOMARKERS IN SCHIZOPHRENIA: A META-ANALYSIS OF MICROARRAY GENE-EXPRESSION DATASETS. European Neuropsychopharmacology, 2019, 29, S1186-S1187.	0.3	O
74	GENOME-WIDE ANALYSES OF REMISSION ON VENLAFAXINE TREATMENT IN OLDER ADULTS WITH LATE-LIFE DEPRESSION. European Neuropsychopharmacology, 2019, 29, S1045-S1046.	0.3	O
75	F103NEW GENETIC FINDINGS IN TARDIVE DYSKINESIA: FROM CYP2D6 TO C4. European Neuropsychopharmacology, 2019, 29, S1165.	0.3	O
76	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. Schizophrenia Research, 2019, 212, 204-212.	1.1	15
77	Impulsivity moderates the effects of dopamine D2 and mixed D1–D2 antagonists in individuals with gambling disorder. Journal of Psychopharmacology, 2019, 33, 1015-1029.	2.0	1
78	Issues In Pharmacogenetic Testing. European Neuropsychopharmacology, 2019, 29, S762.	0.3	0
79	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109659.	2.5	9
80	The comingâ€ofâ€age of pharmacogenetic testing in clinical psychiatry. Psychiatry and Clinical Neurosciences, 2019, 73, 203-203.	1.0	1
81	Associations Between Attention-Deficit/Hyperactivity Disorder and Various Eating Disorders: A Swedish Nationwide Population Study Using Multiple Genetically Informative Approaches. Biological Psychiatry, 2019, 86, 577-586.	0.7	43
82	Copy number variant syndromes are frequent in schizophrenia: Progressing towards a CNV-schizophrenia model. Schizophrenia Research, 2019, 209, 171-178.	1.1	5
83	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	9.4	1,191
84	REPLICATION OF TWO INDEPENDENT LOCI IN HLA-DQB1 AND HLA-B CONTRIBUTING TO THE RISK OF CLOZAPINE-INDUCED AGRANULOCYTOSIS. European Neuropsychopharmacology, 2019, 29, S939.	0.3	1
85	DNA METHYLATION AND 5-HTTLPR GENOTYPE OF THE SEROTONIN TRANSPORTER GENE (SLC6A4) IN ANTIDEPRESSANT TREATMENT RESPONSE OF MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S1001-S1002.	0.3	2
86	PHARMACOGENETIC TESTING HELPS TO REDUCE BENZODIAZEPINE AND SLEEP MEDICATION USE IN PATIENTS WITH ANXIETY. European Neuropsychopharmacology, 2019, 29, S892.	0.3	0
87	An examination of genes, stress and suicidal behavior in two First Nations communities: The role of the brain-derived neurotropic factor gene. Psychiatry Research, 2019, 275, 247-252.	1.7	4
88	Populationâ€based identityâ€byâ€descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 223-231.	1.1	2
89	Adequate evidence to support improved outcomes in depression by primary care physicians compared to psychiatrists when using combinatorial pharmacogenomics. Journal of Psychiatric Research, 2019, 117, 151-152.	1.5	1
90	Genome-Wide Association Study of Sleep Disturbances in Depressive Disorders. Molecular Neuropsychiatry, 2019, 5, 34-43.	3.0	1

#	Article	IF	Citations
91	Association Study of the Complement Component C4 Gene in Tardive Dyskinesia. Frontiers in Pharmacology, 2019, 10, 1339.	1.6	11
92	MITOCHONDRIAL DNA SNPS ASSOCIATED WITH SCHIZOPHRENIA EXHIBIT HIGHLY VARIABLE INTER-ALLELIC HAPLOGROUP AFFILIATION AND NUCLEAR GENOGEOGRAPHIC AFFINITY: BI-GENOMIC LINKAGE DISEQUILIBRIUM RAISES MAJOR CONCERN FOR LINK TO DISEASE. European Neuropsychopharmacology, 2019, 29, S781.	0.3	0
93	SU97EFFECT OF PHARMACOGENETICS-GUIDED ANTIDEPRESSANT TREATMENT ON SUICIDAL IDEATION. European Neuropsychopharmacology, 2019, 29, S1317.	0.3	O
94	F24SYSTEMS BIOLOGY APPROACH TO EVALUATE GENETIC FACTORS OF ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS WITH SCHIZOPHRENIA. European Neuropsychopharmacology, 2019, 29, S1122.	0.3	O
95	M30 ASSOCIATION STUDY OF MITOCHONDRIAL DNA VARIANTS AND SLEEP DISTURBANCES IN MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S182-S183.	0.3	O
96	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	13.5	935
97	BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. Pharmacogenomics Journal, 2019, 19, 269-276.	0.9	11
98	The effect of ethnicity and immigration on treatment resistance in schizophrenia. Comprehensive Psychiatry, 2019, 89, 28-32.	1.5	5
99	Peripheral Biomarkers in Schizophrenia: A Meta-Analysis of Microarray Gene Expression Datasets. International Journal of Neuropsychopharmacology, 2019, 22, 186-193.	1.0	19
100	Oxytocin and its association with reward-based personality traits: A multilocus genetic profile (MLGP) approach. Personality and Individual Differences, 2019, 138, 231-236.	1.6	4
101	Sex differences in schizophrenia: estrogen and mitochondria. Neuropsychopharmacology, 2019, 44, 216-217.	2.8	9
102	Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. Journal of Neural Transmission, 2019, 126, 27-33.	1.4	13
103	Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. Psychiatry Research, 2019, 279, 111-115.	1.7	33
104	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. World Journal of Biological Psychiatry, 2019, 20, 91-95.	1.3	8
105	Alternating optimization for G $\tilde{A}-E$ modelling with weighted genetic and environmental scores: Examples from the MAVAN study Psychological Methods, 2019, 24, 196-216.	2.7	8
106	Dr Nurnberger and Colleagues Reply. Journal of Clinical Psychiatry, 2019, 80, .	1.1	0
107	Association study of BDNF and DRD3 genes with alcohol use disorder in Schizophrenia. Neuroscience Letters, 2018, 671, 1-6.	1.0	11
108	GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. Journal of Psychiatric Research, 2018, 99, 62-68.	1.5	60

#	Article	IF	CITATIONS
109	Genetics of tardive dyskinesia: Promising leads and ways forward. Journal of the Neurological Sciences, 2018, 389, 28-34.	0.3	35
110	Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study. Journal of Psychiatric Research, 2018, 96, 265-272.	1.5	28
111	Association between maternal childhood maltreatment and mother-infant attachment disorganization: Moderation by maternal oxytocin receptor gene and cortisol secretion. Hormones and Behavior, 2018, 102, 23-33.	1.0	19
112	A Comprehensive Analysis of Nuclear-Encoded Mitochondrial Genes in Schizophrenia. Biological Psychiatry, 2018, 83, 780-789.	0.7	35
113	New findings in pharmacogenetics of schizophrenia. Current Opinion in Psychiatry, 2018, 31, 200-212.	3.1	36
114	DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations. Neuroscience Letters, 2018, 669, 14-23.	1.0	54
115	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2018, 19, S97-S105.	1.3	11
116	Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Pharmacogenomics Journal, 2018, 18, 406-412.	0.9	17
117	Fetal growth interacts with multilocus genetic score reflecting dopamine signaling capacity to predict spontaneous sugar intake inÂchildren. Appetite, 2018, 120, 596-601.	1.8	23
118	The dopamine D4 receptor gene, birth weight, maternal depression, maternal attention, and the prediction of disorganized attachment at 36 months of age: A prospective gene × environment analysis. , 2018, 50, 64-77.		10
119	Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis. Molecular Psychiatry, 2018, 23, 1181-1188.	4.1	400
120	Dopamine receptor D2 (DRD2), dopamine transporter solute carrier family C6, member 4 (SLC6A3), and catechol-O-methyltransferase (COMT) genes as moderators of the relation between maternal history of maltreatment and infant emotion regulation. Development and Psychopathology, 2018, 30, 581-592.	1.4	8
121	Schizophrenia-associated mt-DNA SNPs exhibit highly variable haplogroup affiliation and nuclear ancestry: Bi-genomic dependence raises major concerns for link to disease. PLoS ONE, 2018, 13, e0208828.	1.1	15
122	Complex spatio-temporal distribution and genomic ancestry of mitochondrial DNA haplogroups in 24,216 Danes. PLoS ONE, 2018, 13, e0208829.	1.1	5
123	Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis. Frontiers in Pharmacology, 2018, 9, 974.	1.6	17
124	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. American Journal of Human Genetics, 2018, 102, 1185-1194.	2.6	119
125	Pharmacogenetic evaluation of a <i>DISP1</i> gene variant in antidepressant treatment of obsessive–compulsive disorder. Human Psychopharmacology, 2018, 33, e2659.	0.7	7
126	Childhood emotional abuse, physical abuse, and neglect are associated with theory of mind decoding accuracy in young adults with depression. Psychiatry Research, 2018, 268, 501-507.	1.7	15

#	Article	IF	CITATIONS
127	The early care environment and DNA methylome variation in childhood. Development and Psychopathology, 2018, 30, 891-903.	1.4	75
128	Sequence Analysis of Drug Target Genes with Suicidal Behavior in Bipolar Disorder Patients. Molecular Neuropsychiatry, 2018, 4, 1-6.	3.0	3
129	The Complex Interaction of Mitochondrial Genetics and Mitochondrial Pathways in Psychiatric Disease. Molecular Neuropsychiatry, 2018, 4, 52-69.	3.0	42
130	Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists. Journal of Psychiatric Research, 2018, 104, 157-162.	1.5	29
131	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. Neuroscience Letters, 2018, 686, 17-22.	1.0	7
132	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell, 2018, 173, 1705-1715.e16.	13.5	623
133	Examining the role of common and rare mitochondrial variants in schizophrenia. PLoS ONE, 2018, 13, e0191153.	1.1	23
134	The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: A transdiagnostic meta – analysis. PLoS ONE, 2018, 13, e0192658.	1.1	17
135	Maternal perceptions of paternal investment are associated with relationship satisfaction and breastfeeding duration in humans Journal of Family Psychology, 2018, 32, 1025-1035.	1.0	12
136	What Should a Psychiatrist Know About Genetics?. Journal of Clinical Psychiatry, 2018, 80, .	1.1	40
137	Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics. World Journal of Biological Psychiatry, 2017, 18, 492-505.	1.3	48
138	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. American Journal of Psychiatry, 2017, 174, 468-475.	4.0	41
139	Association study between the neurexin†gene and tardive dyskinesia. Human Psychopharmacology, 2017, 32, e2568.	0.7	9
140	Investigation of correlations between DNA methylation, suicidal behavior and aging. Bipolar Disorders, 2017, 19, 32-40.	1.1	27
141	Assessing the risk for suicide in schizophrenia according to migration, ethnicity and geographical ancestry. BMC Psychiatry, 2017, 17, 63.	1.1	4
142	Cognitive and psychosocial function in retired professional hockey players. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 512-519.	0.9	51
143	Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. American Journal of Psychiatry, 2017, 174, 850-858.	4.0	410
144	Polymorphisms of the oxytocin receptor gene and overeating: the intermediary role of endophenotypic risk factors. Nutrition and Diabetes, 2017, 7, e279-e279.	1.5	21

#	Article	IF	CITATIONS
145	Genetic epistasis regulates amyloid deposition in resilient aging. Alzheimer's and Dementia, 2017, 13, 1107-1116.	0.4	8
146	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	4.0	685
147	The Drosophila foraging gene human orthologue PRKG1 predicts individual differences in the effects of early adversity on maternal sensitivity. Cognitive Development, 2017, 42, 62-73.	0.7	15
148	Prenatal maternal depression and child serotonin transporter linked polymorphic region (<i>5-HTTLPR</i>) and dopamine receptor D4 (<i>DRD4</i>) genotype predict negative emotionality from 3 to 36 months. Development and Psychopathology, 2017, 29, 901-917.	1.4	76
149	GENETIC VARIATION AND EPIGENETIC MODIFICATION OF SKA2: ASSOCIATIONS WITH OBSESSIVE-COMPULSIVE DISORDER DISEASE RISK AND SYMPTOM SEVERITY. European Neuropsychopharmacology, 2017, 27, S388-S389.	0.3	O
150	Preliminary Model For The Genetic Prediction Of Clozapine Response. European Neuropsychopharmacology, 2017, 27, S456.	0.3	0
151	Maternal DRD2, SLC6A3, and OXTR genotypes as potential moderators of the relation between maternal history of care and maternal cortisol secretion in the context of mother-infant separation. Biological Psychology, 2017, 129, 154-164.	1.1	4
152	227. Validation Study in Two Genome-Wide Significant Risk Variants for Antipsychotic-Induced Weight Gain. Biological Psychiatry, 2017, 81, S93-S94.	0.7	0
153	Pattern of gene expression in different stages of schizophrenia: Down-regulation of NPTX2 gene revealed by a meta-analysis of microarray datasets. European Neuropsychopharmacology, 2017, 27, 1054-1063.	0.3	28
154	5. Mitochondrial DNA Haplogroups are Associated with Psychiatric Disease: A Nation-Wide Study of 74,763 Danes. Biological Psychiatry, 2017, 81, S3.	0.7	0
155	912. The Relationship between Inflammatory Genes and Cognitive Flexibility among Adolescents with Bipolar Disorder. Biological Psychiatry, 2017, 81, S368-S369.	0.7	O
156	Quantifying dimensional severity of obsessive-compulsive disorder for neurobiological research. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 206-212.	2.5	3
157	Applying deep neural networks to unstructured text notes in electronic medical records for phenotyping youth depression. Evidence-Based Mental Health, 2017, 20, 83-87.	2.2	51
158	232. Genome-Wide Association Study of Venlafaxine Treatment Remission in Late-Life Depression. Biological Psychiatry, 2017, 81, S95-S96.	0.7	1
159	A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain. Schizophrenia Research, 2017, 187, 67-73.	1.1	18
160	A <scp>DRD</scp> 4 gene by maternal sensitivity interaction predicts risk for overweight or obesity in two independent cohorts of preschool children. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2017, 58, 180-188.	3.1	14
161	A review of molecular genetic studies of neurocognitive deficits in schizophrenia. Neuroscience and Biobehavioral Reviews, 2017, 72, 50-67.	2.9	47
162	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	9.4	838

#	Article	IF	Citations
163	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World Journal of Biological Psychiatry, 2017, 18, 5-28.	1.3	75
164	Thinking and doing: the effects of dopamine and oxytocin genes and executive function on mothering behaviours. Genes, Brain and Behavior, 2017, 16, 285-295.	1.1	14
165	Parallel role for the dopamine D1 receptor in gambling and amphetamine reinforcement in healthy volunteers. Journal of Psychopharmacology, 2017, 31, 31-42.	2.0	9
166	Investigating Cortical Inhibition in First-Degree Relatives and Probands in Schizophrenia. Scientific Reports, 2017, 7, 43629.	1.6	17
167	Binge Eating Disorder (BED) in Relation to Addictive Behaviors and Personality Risk Factors. Frontiers in Psychology, 2017, 8, 579.	1.1	17
168	Dynamic interaction between fetal adversity and a genetic score reflecting dopamine function on developmental outcomes at 36 months. PLoS ONE, 2017, 12, e0177344.	1.1	4
169	Verbal memory improvement in first-episode psychosis APOE- ε4 carriers: a pleiotropic effect?. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2945-2953.	1.0	6
170	The role of the ITIH3 rs2535629 variant in antipsychotic response. Schizophrenia Research, 2016, 176, 131-135.	1,1	23
171	Sex differences in subjective and objective responses to a stimulant medication (methylphenidate): Comparisons between overweight/obese adults with and without bingeâ€eating disorder. International Journal of Eating Disorders, 2016, 49, 473-481.	2.1	18
172	Tryptophan hydroxylase 1 gene polymorphisms alter prefrontal cortex activation during response inhibition Neuropsychology, 2016, 30, 18-27.	1.0	4
173	2.47 THE DOPAMINE D4 RECEPTOR GENE, BIRTH WEIGHT, EARLY MATERNAL CARE, MATERNAL DEPRESSION OVER THE POSTNATAL TIME PERIOD, AND THE PREDICTION OF DISORGANIZED ATTACHMENT AT 36-MONTHS OF AGE: A PROSPECTIVE GENE X ENVIRONMENT ANALYSIS. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S135-S136.	0.3	2
174	Admixture analysis of age at onset in first episode bipolar disorder. Journal of Affective Disorders, 2016, 201, 88-94.	2.0	14
175	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Brain, 2016, 139, 2050-2062.	3.7	53
176	Cerebrovascular and microglial states are not altered by functional neuroinflammatory gene variant. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 819-830.	2.4	5
177	Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. Pharmacogenomics Journal, 2016, 16, 352-356.	0.9	37
178	Possible association between the prolactin receptor gene and callous-unemotional traits among aggressive children. Psychiatric Genetics, 2016, 26, 48-51.	0.6	2
179	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. Molecular Neuropsychiatry, 2016, 2, 185-197.	3.0	14
180	Differential Allelic Expression of HTR1B in Suicide Victims: Genetic and Epigenetic Effect of the <l>Cis</l> -Acting Variants. Neuropsychobiology, 2016, 74, 144-149.	0.9	1

#	Article	IF	CITATIONS
181	Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain. Neuropsychobiology, 2016, 74, 169-175.	0.9	4
182	Genetic association analysis of Nâ€methylâ€ <scp>d</scp> â€aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine. Human Psychopharmacology, 2016, 31, 121-134.	0.7	19
183	Increased Nigral <i>SLC6A3</i> Activity in Schizophrenia Patients: Findings From the Toronto–McLean Cohorts. Schizophrenia Bulletin, 2016, 42, 772-781.	2.3	10
184	FKBP5 interacts with maltreatment in children with extreme, pervasive, and persistent aggression. Psychiatry Research, 2016, 242, 277-280.	1.7	11
185	Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases. Schizophrenia Bulletin, 2016, 42, 1176-1184.	2.3	62
186	Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage. Pharmacogenomics, 2016, 17, 199-208.	0.6	5
187	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv132.	1.0	50
188	Mechanisms of the placebo effect in pain and psychiatric disorders. Pharmacogenomics Journal, 2016, 16, 491-500.	0.9	36
189	Genetic Differential Susceptibility to Socioeconomic Status and Childhood Obesogenic Behavior. JAMA Pediatrics, 2016, 170, 359.	3.3	76
190	Prefrontal White Matter Structure Mediates the Influence of GAD1 on Working Memory. Neuropsychopharmacology, 2016, 41, 2224-2231.	2.8	23
191	Limited Evidence for Association of Genome-Wide Schizophrenia Risk Variants on Cortical Neuroimaging Phenotypes. Schizophrenia Bulletin, 2016, 42, 1027-1036.	2.3	11
192	Preliminary evidence for association of genome-wide significant <i>DRD2</i> schizophrenia risk variant with clozapine response. Pharmacogenomics, 2016, 17, 103-109.	0.6	37
193	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2016, 17, 221-229.	1.3	24
194	Serotonin and Dopamine Gene Variation and Theory of Mind Decoding Accuracy in Major Depression: A Preliminary Investigation. PLoS ONE, 2016, 11, e0150872.	1.1	18
195	The interplay of birth weight, dopamine receptor D4 gene (DRD4), and early maternal care in the prediction of disorganized attachment at 36 months of age. Development and Psychopathology, 2015, 27, 1145-1161.	1.4	28
196	BDNF Val66Met polymorphism and stressful life events in melancholic childhood-onset depression. Psychiatric Genetics, 2015, 25, 249-255.	0.6	5
197	The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies. Current Neuropharmacology, 2015, 13, 802-814.	1.4	52
198	COMT and MAO-A Polymorphisms and Obsessive-Compulsive Disorder: A Family-Based Association Study. PLoS ONE, 2015, 10, e0119592.	1,1	18

#	Article	IF	CITATIONS
199	Gender differences in the association between stop-signal reaction times, body mass indices and/or spontaneous food intake in pre-school children: an early model of compromised inhibitory control and obesity. International Journal of Obesity, 2015, 39, 614-619.	1.6	51
200	Physicians' opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Research, 2015, 229, 913-918.	1.7	51
201	DRD2 and SLC6A3 moderate impact of maternal depressive symptoms on infant cortisol. Psychoneuroendocrinology, 2015, 62, 243-251.	1.3	16
202	Investigation of <i>TSPO</i> variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics, 2015, 16, 5-22.	0.6	15
203	Mitochondrial dysfunction in schizophrenia: an evolutionary perspective. Human Genetics, 2015, 134, 13-21.	1.8	28
204	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. American Journal of Psychiatry, 2015, 172, 82-93.	4.0	117
205	Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience, 2015, 18, 199-209.	7.1	701
206	The role of genetic variation across IL- $1\hat{l}^2$, IL- 2 , IL- 6 , and BDNF in antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2015, 16, 45-56.	1.3	28
207	Maternal childhood adversity and child temperament: An association moderated by child 5â€ <scp>HTTLPR</scp> genotype. Genes, Brain and Behavior, 2015, 14, 229-237.	1.1	34
208	Interactions between childhood maltreatment and brain-derived neurotrophic factor and serotonin transporter polymorphisms on depression symptoms. Psychiatry Research, 2015, 229, 609-612.	1.7	14
209	Childhood emotional and sexual maltreatment moderate the relation of the serotonin transporter gene to stress generation Journal of Abnormal Psychology, 2015, 124, 275-287.	2.0	29
210	A genome-wide association study of suicide severity scores in bipolar disorder. Journal of Psychiatric Research, 2015, 65, 23-29.	1.5	36
211	Age at onset mixture analysis and systematic comparison in schizophrenia spectrum disorders: Is the onset heterogeneity dependent on heterogeneous diagnosis?. Schizophrenia Research, 2015, 164, 83-91.	1.1	15
212	Prenatal depression and 5â€ <scp>HTTLPR</scp> interact to predict dysregulation from 3 to 36Âmonths – A differential susceptibility model. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2015, 56, 21-29.	3.1	56
213	Genetic variation in CYP3A43 is associated with response to antipsychotic medication. Journal of Neural Transmission, 2015, 122, 29-34.	1.4	25
214	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. JAMA Psychiatry, 2015, 72, 268.	6.0	700
215	Association Study of GABAA α2 Receptor Subunit Gene Variants in Antipsychotic-Associated Weight Gain. Journal of Clinical Psychopharmacology, 2015, 35, 7-12.	0.7	18
216	Meta-analysis and association of brain-derived neurotrophic factor (BDNF) gene with obsessive-compulsive disorder. Psychiatric Genetics, 2015, 25, 95-96.	0.6	13

#	Article	IF	Citations
217	A preliminary candidate gene study in body dysmorphic disorder. Journal of Obsessive-Compulsive and Related Disorders, 2015, 6, 72-76.	0.7	7
218	Effects of Genotype and Sleep on Temperament. Pediatrics, 2015, 136, e914-e921.	1.0	20
219	Genetic variation in <i>IL-1β, IL-2, IL-6, TSPO</i> and <i>BDNF</i> and response to duloxetine or placebo treatment in major depressive disorder. Pharmacogenomics, 2015, 16, 1919-1929.	0.6	19
220	Investigation of the genetic interaction between <i>BDNF</i> and <i>DRD3</i> genes in suicidal behaviour in psychiatric disorders. World Journal of Biological Psychiatry, 2015, 16, 171-179.	1.3	14
221	Addiction-related genes in gambling disorders: new insights from parallel human and pre-clinical models. Molecular Psychiatry, 2015, 20, 1002-1010.	4.1	38
222	Association between MC4R rs17782313 polymorphism and overeating behaviors. International Journal of Obesity, 2015, 39, 114-120.	1.6	49
223	Preschool children without 7-repeat DRD4 gene more likely to develop disorganized attachment style. McGill Science Undergraduate Research Journal, 2015, 10, 31-36.	0.1	2
224	Genetic variation in the <i>GCG </i> and in the <i>GLP1R </i> penes and antipsychotic-induced weight gain. Pharmacogenomics, 2014, 15, 423-431.	0.6	12
225	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1347-1354.	2.8	26
226	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications, 2014, 5, 4757.	5.8	153
227	Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. Molecular Psychiatry, 2014, 19, 403-405.	4.1	20
228	Food cravings, appetite, and snack-food consumption in response to a psychomotor stimulant drug: the moderating effect of \tilde{A} ¢ \hat{a} , \tilde{A} "food-addiction \tilde{A} ¢ \hat{a} , \tilde{A} . Frontiers in Psychology, 2014, 5, 403.	1.1	43
229	Positive perception of pharmacogenetic testing for psychotropic medications. Human Psychopharmacology, 2014, 29, 287-291.	0.7	18
230	Brain White Matter Development Is Associated with a Human-Specific Haplotype Increasing the Synthesis of Long Chain Fatty Acids. Journal of Neuroscience, 2014, 34, 6367-6376.	1.7	27
231	The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan. Molecular Psychiatry, 2014, 19, 1125-1132.	4.1	39
232	Lack of association between dopamine- \hat{l}^2 hydroxylase gene and a history of suicide attempt in schizophrenia. Psychiatric Genetics, 2014, 24, 110-115.	0.6	3
233	The social and economic burden of treatment-resistant schizophrenia. International Clinical Psychopharmacology, 2014, 29, 63-76.	0.9	289
234	Fat Mass- and Obesity-Associated (FTO) Gene and Antipsychotic-Induced Weight Gain: An Association Study. Neuropsychobiology, 2014, 69, 59-63.	0.9	16

#	Article	IF	Citations
235	Association Study of <i>GABRG2</i> Polymorphisms with Suicidal Behaviour in Schizophrenia Patients with Alcohol Use Disorder. Neuropsychobiology, 2014, 69, 154-158.	0.9	12
236	Association between the seven-repeat allele of the dopamine-4 receptor gene (DRD4) and spontaneous food intake in pre-school children. Appetite, 2014, 73, 15-22.	1.8	30
237	The role of leptin, melanocortin, and neurotrophin system genes on body weight in anorexia nervosa and bulimia nervosa. Journal of Psychiatric Research, 2014, 55, 77-86.	1.5	25
238	Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics Journal, 2014, 14, 176-181.	0.9	56
239	Treating Working Memory Deficits in Schizophrenia: A Review of the Neurobiology. Biological Psychiatry, 2014, 75, 361-370.	0.7	202
240	Does a history of suicide attempt predict higher antipsychotic dosage in schizophrenia?. Psychopharmacology, 2014, 231, 2507-13.	1.5	3
241	Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 303-313.	1.1	76
242	Genome-wide association study of bipolar disorder in Canadian and UK populations corroborates disease loci including SYNE1 and CSMD1. BMC Medical Genetics, 2014, 15, 2.	2.1	106
243	Protein kinase cAMP-dependent regulatory type II beta (<i>PRKAR2B</i>) gene variants in antipsychotic-induced weight gain. Human Psychopharmacology, 2014, 29, 330-335.	0.7	10
244	The role of tyrosine hydroxylase gene variants in suicide attempt in schizophrenia. Neuroscience Letters, 2014, 559, 39-43.	1.0	8
245	Pharmacogenetics of antidepressant treatment in obsessive–compulsive disorder: an update and implications for clinicians. Pharmacogenomics, 2014, 15, 1147-1157.	0.6	41
246	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World Journal of Biological Psychiatry, 2014, 15, 404-410.	1.3	17
247	Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2014, 15, 251-258.	1.3	5
248	Biological insights from 108 schizophrenia-associated genetic loci. Nature, 2014, 511, 421-427.	13.7	6,934
249	Use of candidate gene markers to guide antipsychotic dosage adjustment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 315-320.	2.5	7
250	Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 910-919.	0.3	111
251	A genome-wide association study of anorexia nervosa. Molecular Psychiatry, 2014, 19, 1085-1094.	4.1	282
252	Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. Journal of Psychiatric Research, 2014, 54, 36-42.	1.5	26

#	Article	IF	CITATIONS
253	Pathological gambling subtypes: A comparison of treatment-seeking and non-treatment-seeking samples from Brazil and Canada. Addictive Behaviors, 2014, 39, 1172-1175.	1.7	20
254	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. Psychiatry Research, 2014, 215, 799-800.	1.7	8
255	No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry Research, 2014, 219, 255-260.	1.7	13
256	Pharmacogenetics of Antipsychotics. Canadian Journal of Psychiatry, 2014, 59, 76-88.	0.9	83
257	The Maternal Adversity, Vulnerability and Neurodevelopment Project: Theory and Methodology. Canadian Journal of Psychiatry, 2014, 59, 497-508.	0.9	76
258	Genetic and Developmental Origins of Food Preferences and Obesity Risk: The Role of Dopamine. Research and Perspectives in Endocrine Interactions, 2014, , 157-174.	0.2	2
259	Finite mixture regression model analysis on antipsychotics induced weight gain: Investigation of the role of the serotonergic genes. European Neuropsychopharmacology, 2013, 23, 224-228.	0.3	8
260	The role of ethnicity in treatment refractory schizophrenia. Comprehensive Psychiatry, 2013, 54, 167-172.	1.5	18
261	Ethnicity and suicide attempt: analysis in bipolar disorder and schizophrenia. BMC Psychiatry, 2013, 13, 252.	1.1	5
262	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 2013, 45, 984-994.	9.4	2,067
263	Quantitative leukocyte BDNF promoter methylation analysis in bipolar disorder. International Journal of Bipolar Disorders, $2013, 1, 28$.	0.8	19
264	Future roles of pharmacogenomic testing and Biomarkers in Psychiatry. International Review of Psychiatry, 2013, 25, 493-493.	1.4	3
265	Association and CpG SNP analysis of HTR4 polymorphisms with suicidal behavior in subjects with schizophrenia. Journal of Neural Transmission, 2013, 120, 253-258.	1.4	9
266	Age at onset of schizophrenia: Cannabis, COMT gene, and their interactions. Schizophrenia Research, 2013, 151, 289-290.	1,1	17
267	Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment?. Pharmacogenomics, 2013, 14, 1273-1281.	0.6	15
268	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research, 2013, 47, 1760-1765.	1.5	55
269	â€~Food addiction' and its association with a dopaminergic multilocus genetic profile. Physiology and Behavior, 2013, 118, 63-69.	1.0	137
270	Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: A preliminary study. Psychiatry Research - Neuroimaging, 2013, 211, 214-220.	0.9	49

#	Article	IF	Citations
271	Genome-wide association study of obsessive-compulsive disorder. Molecular Psychiatry, 2013, 18, 788-798.	4.1	312
272	The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Molecular Psychiatry, 2013, 18, 443-450.	4.1	110
273	Analysis of CpG SNPs in 34 genes: Association test with suicide attempt in schizophrenia. Schizophrenia Research, 2013, 147, 262-268.	1.1	14
274	Study of the Catecholâ€Oâ€Methyltransferase (COMT) Gene with High Aggression in Children. Aggressive Behavior, 2013, 39, 45-51.	1.5	54
275	Oligodendrocyte Genes, White Matter Tract Integrity, and Cognition in Schizophrenia. Cerebral Cortex, 2013, 23, 2044-2057.	1.6	69
276	Analysis of 34 candidate genes in bupropion and placebo remission. International Journal of Neuropsychopharmacology, 2013, 16, 771-781.	1.0	34
277	Incorporating psychiatric pharmacogenetics into family practice. Pharmacogenomics, 2013, 14, 1121-1124.	0.6	3
278	Possible Association of Nicotinic Acetylcholine Receptor Gene (CHRNA4 and CHRNB2) Polymorphisms with Nicotine Dependence in Japanese Males: An Exploratory Study. Pharmacopsychiatry, 2013, 46, 77-82.	1.7	10
279	Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. PLoS Genetics, 2013, 9, e1003864.	1.5	241
280	Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients. Journal of Clinical Psychopharmacology, 2013, 33, 11-17.	0.7	44
281	Exploratory study on association of genetic variation in <i>TBC1D1</i> with antipsychoticâ€induced weight gain. Human Psychopharmacology, 2013, 28, 183-187.	0.7	14
282	Genetic variation in oxytocin rs2740210 and early adversity associated with postpartum depression and breastfeeding duration. Genes, Brain and Behavior, 2013, 12, 681-694.	1.1	89
283	Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics Journal, 2013, 13, 272-279.	0.9	49
284	Estimating the heritability of reporting stressful life events captured by common genetic variants. Psychological Medicine, 2013, 43, 1965-1971.	2.7	46
285	Association of the iPLA2 \hat{l}^2 gene with bipolar disorder and assessment of its interaction with TRPM2 gene polymorphisms. Psychiatric Genetics, 2013, 23, 86-89.	0.6	12
286	Interaction between Oxytocin Genotypes and Early Experience Predicts Quality of Mothering and Postpartum Mood. PLoS ONE, 2013, 8, e61443.	1.1	110
287	Translocator Protein (18 kDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [¹⁸ F]-FEPPA. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 968-972.	2.4	131
288	A putative model of overeating and obesity based on brain-derived neurotrophic factor: Direct and indirect effects Behavioral Neuroscience, 2012, 126, 505-514.	0.6	8

#	Article	IF	CITATIONS
289	Functional studies and rare variant screening of SLC1A1/EAAC1 in males with obsessive–compulsive disorder. Psychiatric Genetics, 2012, 22, 256-260.	0.6	18
290	Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics Journal, 2012, 12, 260-266.	0.9	26
291	A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Molecular Psychiatry, 2012, 17, 728-740.	4.1	117
292	An exploration of the oligodendrocyte lineage transcription factor 2 gene and obsessive-compulsive disorder. Psychiatric Genetics, 2012, 22, 149.	0.6	1
293	The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. International Journal of Neuropsychopharmacology, 2012, 15, 181-187.	1.0	47
294	Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes. Pharmacogenetics and Genomics, 2012, 22, 807-811.	0.7	20
295	The brain-derived neurotrophic factor gene in suicidal behaviour: a meta-analysis. International Journal of Neuropsychopharmacology, 2012, 15, 1037-1042.	1.0	71
296	Possible genetic association between vasopressin receptor 1B and child aggression. Psychiatry Research, 2012, 200, 784-788.	1.7	36
297	The role of ANKK1 and TTC12 genes on drinking behaviour in tobacco dependent subjects1. World Journal of Biological Psychiatry, 2012, 13, 232-238.	1.3	2
298	Dopaminergic system genes in childhood aggression: Possible role for DRD2. World Journal of Biological Psychiatry, 2012, 13, 65-74.	1.3	64
299	Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain. Pharmacogenomics Journal, 2012, 12, 156-164.	0.9	54
300	Association study of early-immediate genes in childhood-onset mood disorders and suicide attempt. Psychiatry Research, 2012, 197, 49-54.	1.7	24
301	Age-related decline in white matter tract integrity and cognitive performance: A DTI tractography and structural equation modeling study. Neurobiology of Aging, 2012, 33, 21-34.	1.5	274
302	CCK-B receptor gene and response to cholecystokinin-tetrapeptide in healthy volunteers. Peptides, 2012, 35, 9-13.	1.2	8
303	Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 62-75.	2.5	34
304	Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 134-141.	2.5	65
305	Binge eating disorder and the dopamine D2 receptor: Genotypes and sub-phenotypes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 328-335.	2.5	98
306	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight Gain. Archives of General Psychiatry, 2012, 69, 904.	13.8	165

#	Article	IF	CITATIONS
307	DRD4 VNTR polymorphism and age at onset of severe mental illnesses. Neuroscience Letters, 2012, 519, 9-13.	1.0	14
308	The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 96-101.	2.5	61
309	Admixture analysis of Age at Onset in Schizophrenia: Genetic Association Study of 45 candidate loci. Schizophrenia Research, 2012, 134, 288-290.	1.1	3
310	Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis. Schizophrenia Research, 2012, 134, 253-259.	1.1	36
311	Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Molecular Psychiatry, 2012, 17, 242-266.	4.1	225
312	The AmpliChip $<$ sup $>$ \hat{A}^{\odot} $<$ /sup $>$ CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism. Genetic Testing and Molecular Biomarkers, 2012, 16, 897-903.	0.3	29
313	Myelin-Associated Glycoprotein Gene and Brain Morphometry in Schizophrenia. Frontiers in Psychiatry, 2012, 3, 40.	1.3	32
314	DISC1 and Striatal Volume: A Potential Risk Phenotype For mental Illness. Frontiers in Psychiatry, 2012, 3, 57.	1.3	13
315	Association study of <i>GRIK1</i> gene polymorphisms in schizophrenia: case–control and familyâ€based studies. Human Psychopharmacology, 2012, 27, 345-351.	0.7	14
316	Dopamine receptors D1 and D2 are related to observed maternal behavior. Genes, Brain and Behavior, 2012, 11, 684-694.	1.1	43
317	Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. Journal of Psychiatric Research, 2012, 46, 462-468.	1.5	26
318	Possible association of the <i>DRD4</i> gene with a history of attentionâ€deficit/hyperactivity disorder in women with bulimia nervosa. International Journal of Eating Disorders, 2012, 45, 622-625.	2.1	11
319	Childhood aggression, callous-unemotional traits and oxytocin genes. European Child and Adolescent Psychiatry, 2012, 21, 125-132.	2.8	81
320	<i>ANK3, CACNA1C</i> and <i>ZNF804A</i> gene variants in bipolar disorders and psychosis subphenotype. World Journal of Biological Psychiatry, 2011, 12, 392-397.	1.3	41
321	The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophrenia Research, 2011, 132, 121-124.	1.1	24
322	Parent of origin effect and differential allelic expression of BDNF Val66Met in suicidal behaviour. World Journal of Biological Psychiatry, 2011, 12, 42-47.	1.3	9
323	Are serotonin 3A and 3B receptor genes associated with suicidal behavior in schizophrenia subjects?. Neuroscience Letters, 2011, 489, 137-141.	1.0	6
324	COMT Val158Met variant and functional haplotypes associated with childhood ADHD history in women with bulimia nervosa. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 948-952.	2. 5	34

#	Article	IF	Citations
325	Admixture analysis of age at onset in bipolar disorder. Psychiatry Research, 2011, 185, 27-32.	1.7	51
326	Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Research, 2011, 185, 450-452.	1.7	6
327	Using a Mobile Laboratory to Study Mental Health, Addictions and Violence: A Research Plan. Challenges, 2011, 2, 1-18.	0.9	12
328	Ethnicity and Age at Onset in Bipolar Spectrum Disorders. CNS Spectrums, 2011, 16, 127-134.	0.7	20
329	Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addiction Biology, 2011, 16, 357-376.	1.4	61
330	Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. Bipolar Disorders, 2011, 13, 198-207.	1.1	33
331	The ZNF804A Gene: Characterization of a Novel Neural Risk Mechanism for the Major Psychoses. Neuropsychopharmacology, 2011, 36, 1871-1878.	2.8	58
332	Opiates, overeating and obesity: a psychogenetic analysis. International Journal of Obesity, 2011, 35, 1347-1354.	1.6	45
333	Gene–gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics, 2011, 12, 277-291.	0.6	22
334	Evidence that †food addiction' is a valid phenotype of obesity. Appetite, 2011, 57, 711-717.	1.8	439
335	Parent of origin effect and allelic expression imbalance of the serotonin transporter in bipolar disorder and suicidal behaviour. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 533-538.	1.8	17
336	Genetics of Antipsychotic-induced Side Effects and Agranulocytosis. Current Psychiatry Reports, 2011, 13, 156-165.	2.1	60
337	Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective. Human Psychopharmacology, 2011, 26, 21-27.	0.7	5
338	Genetic interactions in the adrenergic system genes: analysis of antipsychoticâ€induced weight gain. Human Psychopharmacology, 2011, 26, 386-391.	0.7	10
339	The Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Prediction of Neural Risk for Alzheimer Disease. Archives of General Psychiatry, 2011, 68, 198.	13.8	117
340	Weak association of the platelet-derived growth factor beta (PDGFB) and PDGF receptor beta (PDGFRB) genes with schizophrenia and schizoaffective disorder. World Journal of Biological Psychiatry, 2011, 12, 127-133.	1.3	5
341	Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nature Genetics, 2011, 43, 977-983.	9.4	1,283
342	Neurexin-1 and Frontal Lobe White Matter: An Overlapping Intermediate Phenotype for Schizophrenia and Autism Spectrum Disorders. PLoS ONE, 2011, 6, e20982.	1.1	58

#	Article	IF	CITATIONS
343	No evidence of an association between two genes, <i>EDN1</i> and <i>ACE</i> , and childhoodâ€onset mood disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 341-346.	1.1	4
344	Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. International Clinical Psychopharmacology, 2010, 25, 264-269.	0.9	4
345	Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatric Genetics, 2010, 20, 39-43.	0.6	13
346	Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenetics and Genomics, 2010, 20, 274-276.	0.7	41
347	"GSK3B and schizophrenia: a case not closed―reply. Psychopharmacology, 2010, 208, 335-336.	1.5	2
348	Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology, 2010, 210, 347-354.	1.5	7
349	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. Journal of Psychiatric Research, 2010, 44, 598-604.	1.5	25
350	Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. Journal of Psychiatric Research, 2010, 44, 700-706.	1.5	39
351	No association between oxytocin or prolactin gene variants and childhood-onset mood disorders. Psychoneuroendocrinology, 2010, 35, 1422-1428.	1.3	15
352	Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychoticâ€induced weight gain in European and Africanâ€American schizophrenia patients. Human Psychopharmacology, 2010, 25, 253-259.	0.7	30
353	Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Human Psychopharmacology, 2010, 25, 582-585.	0.7	16
354	Association of polymorphisms in the <i>BDNF</i> , <i>DRD1</i> and <i>DRD3</i> genes with tobacco smoking in schizophrenia. Annals of Human Genetics, 2010, 74, 291-298.	0.3	54
355	Association of the <i>GABRD</i> gene and childhoodâ€onset mood disorders. Genes, Brain and Behavior, 2010, 9, 668-672.	1.1	34
356	Replicated association of the <i>NR4A3</i> gene with smoking behaviour in schizophrenia and in bipolar disorder. Genes, Brain and Behavior, 2010, 9, 910-917.	1.1	22
357	Meta-analysis and imputation refines the association of $15q25$ with smoking quantity. Nature Genetics, $2010,42,436-440.$	9.4	581
358	Association analysis of <i>DAOA</i> and <i>DAO</i> in bipolar disorder: results from two independent caseâ€control studies. Bipolar Disorders, 2010, 12, 579-581.	1.1	9
359	Polymorphisms of the <i>HTR2C </i> gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics, 2010, 11, 1561-1571.	0.6	99
360	Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure. Journal of Clinical Pharmacology, 2010, 50, 62-72.	1.0	60

#	Article	IF	CITATIONS
361	Diffusion tensor tractography findings in schizophrenia across the adult lifespan. Brain, 2010, 133, 1494-1504.	3.7	131
362	Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Injury, 2010, 24, 959-969.	0.6	53
363	Smoking in adult attention-deficit/hyperactivity disorder: Interaction between 15q13 nicotinic genes and Temperament Character Inventory scores. World Journal of Biological Psychiatry, 2010, 11, 506-510.	1.3	3
364	A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology, 2010, 35, 1315-1324.	2.8	95
365	A Season-of-Birth/DRD4 Interaction Predicts Maximal Body Mass Index in Women with Bulimia Nervosa. Neuropsychopharmacology, 2010, 35, 1729-1733.	2.8	29
366	Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. NeuroImage, 2010, 52, 50-54.	2.1	83
367	The catechol- <i>O</i> -methyl-transferase gene in tardive dyskinesia. World Journal of Biological Psychiatry, 2010, 11, 803-812.	1.3	25
368	Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics Journal, 2010, 10, 200-218.	0.9	64
369	Association of HPA axis genes with suicidal behaviour in schizophrenia. Journal of Psychopharmacology, 2010, 24, 677-682.	2.0	55
370	Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects. Biological Psychology, 2010, 85, 33-37.	1.1	105
371	Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 50-56.	2.5	51
372	Cocaine and amphetamine regulated transcript (CART) gene in the comorbidity of schizophrenia with alcohol use disorders and nicotine dependence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 834-836.	2.5	8
373	Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case–control and family based study designs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1412-1418.	2.5	18
374	Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1484-1490.	2.5	18
375	Comorbidity between bipolar disorder and alcohol use disorder: Association of dopamine and serotonin gene polymorphisms. Psychiatry Research, 2010, 176, 30-33.	1.7	24
376	Lack of association between HTR4 gene polymorphisms and schizophrenia in case–control and family-based samples. Psychiatry Research, 2010, 175, 176-178.	1.7	6
377	Variants in the oxytocin gene and risk for schizophrenia. Schizophrenia Research, 2010, 121, 279-280.	1.1	46
378	Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. International Journal of Neuropsychopharmacology, 2010, 13, 793-798.	1.0	60

#	Article	IF	Citations
379	Mixture regression analysis on age at onset in Bipolar Disorder patients: Investigation of the role of serotonergic genes. European Neuropsychopharmacology, 2010, 20, 663-670.	0.3	15
380	Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. European Neuropsychopharmacology, 2010, 20, 688-694.	0.3	14
381	Smoking in adult attention-deficit/hyperactivity disorder: Interaction between 15q13 nicotinic genes and Temperament Character Inventory scores. World Journal of Biological Psychiatry, 2010, 11, 1-5.	1.3	2
382	Progress in Genetic Studies of Schizophrenia. , 2010, , 233-248.		0
383	Genetics in schizophrenia: where are we and what next?. Dialogues in Clinical Neuroscience, 2010, 12, 289-303.	1.8	44
384	The GABA A-Receptor \hat{I}^32 (GABRG2) Gene in obsessive-compulsive disorder. Revista Brasileira De Psiquiatria, 2009, 31, 328-331.	0.9	8
385	Association of the α2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European–Americans. Pharmacogenomics, 2009, 10, 1169-1176.	0.6	48
386	Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7501-7506.	3.3	274
387	Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Human Molecular Genetics, 2009, 18, 3227-3243.	1.4	160
388	Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive–compulsive disorder. Psychiatry Research - Neuroimaging, 2009, 172, 136-139.	0.9	82
389	Methylation and QTDT analysis of the 5-HT2A receptor 102C allele: Analysis of suicidality in major psychosis. Journal of Psychiatric Research, 2009, 43, 532-537.	1.5	58
390	A psycho-genetic study of associations between the symptoms of binge eating disorder and those of attention deficit (hyperactivity) disorder. Journal of Psychiatric Research, 2009, 43, 687-696.	1.5	40
391	Genome scan in sibling pairs with juvenileâ€onset mood disorders: Evidence for linkage to 13q and Xq. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 638-646.	1.1	10
392	Tagging SNP association study of the ILâ€lî² gene (<i>IL1B</i>) and childhoodâ€onset mood disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 653-659.	1.1	11
393	<i>G72/G30</i> (<i>DAOA</i>) and juvenileâ€onset mood disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 1007-1012.	1.1	13
394	Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. Human Psychopharmacology, 2009, 24, 676-679.	0.7	16
395	Neuregulin 1 and age of onset in the major psychoses. Journal of Neural Transmission, 2009, 116, 479-486.	1.4	7
396	Glutamate System Genes Associated with Ventral Prefrontal and Thalamic Volume in Pediatric Obsessive-Compulsive Disorder. Brain Imaging and Behavior, 2009, 3, 64-76.	1.1	45

#	Article	IF	CITATIONS
397	Genetic aspects of pathological gambling: a complex disorder with shared genetic vulnerabilities. Addiction, 2009, 104, 1454-1465.	1.7	95
398	<i>TRPM2</i> variants and bipolar disorder risk: confirmation in a familyâ€based association study. Bipolar Disorders, 2009, 11, 1-10.	1.1	52
399	Further genetic evidence implicates the vasopressin system in childhoodâ€onset mood disorders. European Journal of Neuroscience, 2009, 30, 1615-1619.	1.2	23
400	Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics Journal, 2009, 9, 168-174.	0.9	29
401	Overview of genetics and obsessive–compulsive disorder. Psychiatry Research, 2009, 170, 7-14.	1.7	87
402	Serotonin genes and gene–gene interactions in borderline personality disorder in a matched case-control study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 128-133.	2.5	56
403	Association of Attention-Deficit/Hyperactivity Disorder with a Candidate Region for Reading Disabilities on Chromosome 6p. Biological Psychiatry, 2009, 66, 368-375.	0.7	49
404	MDR1 gene in tardive dyskinesia scale scores: Comparison of strategies for quantitative trait haplotype analysis. Schizophrenia Research, 2009, 110, 200-201.	1.1	8
405	Genetic association and post-mortem brain mRNA analysis of DISC1 and related genes in schizophrenia. Schizophrenia Research, 2009, 114, 39-49.	1.1	46
406	Association study of the gamma-aminobutyric acid type a receptor \hat{I}^32 subunit gene with schizophrenia. Schizophrenia Research, 2009, 114, 33-38.	1.1	12
407	Association of a polymorphism in the NRXN3 gene with the degree of smoking in schizophrenia: A preliminary study. World Journal of Biological Psychiatry, 2009, 10, 929-935.	1.3	41
408	Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. European Neuropsychopharmacology, 2009, 19, 317-328.	0.3	45
409	Quantitative examination of a novel clustering method using magnetic resonance diffusion tensor tractography. Neurolmage, 2009, 45, 370-376.	2.1	46
410	Dopamine for "Wanting―and Opioids for "Liking― A Comparison of Obese Adults With and Without Binge Eating. Obesity, 2009, 17, 1220-1225.	1.5	257
411	Association study of N-methyl-D-aspartate glutamate receptor subunit genes and childhood-onset mood disorders. Psychiatric Genetics, 2009, 19, 156-157.	0.6	6
412	Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology, 2008, 200, 177-186.	1.5	58
413	MAG Gene Variation and Cortical Gray Matter Volume in First Episode Schizophrenia. Brain Imaging and Behavior, 2008, 2, 117-122.	1.1	3
414	Association Study of Theta EEG Asymmetry and Brain-derived Neurotrophic Factor Gene Variants in Childhood-onset Mood Disorder. NeuroMolecular Medicine, 2008, 10, 343-355.	1.8	13

#	Article	IF	CITATIONS
415	Functional Polymorphism of the Human Multidrug Resistance Gene (MDR1) and Polydipsia–Hyponatremia in Schizophrenia. NeuroMolecular Medicine, 2008, 10, 362-367.	1.8	22
416	5-ht2c receptor and mao-a interaction analysis: no association with suicidal behaviour in bipolar patients. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 428-433.	1.8	17
417	A DRD4/BDNF gene–gene interaction associated with maximum BMI in women with bulimia nervosa. International Journal of Eating Disorders, 2008, 41, 22-28.	2.1	61
418	Personality and eating behaviors: A case–control study of binge eating disorder. International Journal of Eating Disorders, 2008, 41, 243-250.	2.1	84
419	No evidence for genetic association between DARPPâ€32 (<i>PP1R1B</i>) polymorphisms and attention deficit hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 339-342.	1.1	2
420	Association study for genes at chromosome $5p13\hat{a} \in q11$ in attention deficit hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 600-605.	1.1	10
421	Serotonin transporter gene and adverse life events in adult ADHD. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1461-1469.	1.1	41
422	Association study of brainâ€derived neurotrophic factor (<i>BDNF</i>) and <i>LINâ€₹</i> homolog (<i>LINâ€₹</i>) genes with adult attentionâ€deficit/hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 945-951.	1.1	45
423	Association of ADHD and the <i>Protogenin </i> gene in the chromosome 15q21.3 reading disabilities linkage region. Genes, Brain and Behavior, 2008, 7, 877-886.	1.1	21
424	Further support for association of the mitochondrial complex I subunit gene NDUFV2 with bipolar disorder. Bipolar Disorders, 2008, 10, 105-110.	1.1	30
425	Investigation of the G protein subunit GÎ \pm olf gene (GNAL) in attention deficit/hyperactivity disorder. Journal of Psychiatric Research, 2008, 42, 117-124.	1.5	27
426	Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia. Schizophrenia Research, 2008, 103, 192-200.	1.1	33
427	Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophrenia Research, 2008, 106, 248-252.	1.1	24
428	Investigation of the dopamine D5 receptor gene (DRD5) in adult attention deficit hyperactivity disorder. Neuroscience Letters, 2008, 432, 50-53.	1.0	15
429	Analysis of BDNF Val66Met allele-specific mRNA levels in bipolar disorder. Neuroscience Letters, 2008, 441, 229-232.	1.0	10
430	Power based association analysis (PBAT) of serotonergic and noradrenergic polymorphisms in bipolar patients with suicidal behaviour. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 197-203.	2.5	18
431	Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 620-628.	2.5	144
432	Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1848-1853.	2.5	32

#	Article	IF	CITATIONS
433	Family history of depression is associated with younger age of onset in patients with recurrent depression. Psychological Medicine, 2008, 38, 641-649.	2.7	53
434	Cytokine Genes <i>TNF</i> , <i>IL1A</i> , <i>IL1B</i> , <i>IL6</i> , <i>IL1RN</i> and <i>IL10</i> , and Childhood-Onset Mood Disorders. Neuropsychobiology, 2008, 58, 71-80.	0.9	56
435	Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics Journal, 2008, 8, 90-100.	0.9	74
436	Association of the Neurotrophic Tyrosine Kinase Receptor 3 (<i>NTRK3</i>) Gene and Childhood-Onset Mood Disorders. American Journal of Psychiatry, 2008, 165, 610-616.	4.0	28
437	The serotonin transporter polymorphisms and major depression following traumatic brain injury. Brain Injury, 2008, 22, 471-479.	0.6	29
438	A family-based association study of the myelin-associated glycoprotein and $2\hat{a}\in^2$, $3\hat{a}\in^2$ -cyclic nucleotide $3\hat{a}\in^2$ -phosphodiesterase genes with schizophrenia. Psychiatric Genetics, 2008, 18, 143-146.	0.6	29
439	Multivariate analyses suggest genetic impacts on neurocircuitry in schizophrenia. NeuroReport, 2008, 19, 603-607.	0.6	25
440	Association study of serotonin system genes in childhood-onset mood disorder. Psychiatric Genetics, 2008, 18, 47-52.	0.6	11
441	Dopamine Transporter Gene (DAT1) Associated with Appetite Suppression to Methylphenidate in a Case–Control Study of Binge Eating Disorder. Neuropsychopharmacology, 2007, 32, 2199-2206.	2.8	60
442	Connexin 50 gene on human chromosome 1q21 is associated with schizophrenia in matched case control and family-based studies. Journal of Medical Genetics, 2007, 44, 532-536.	1.5	48
443	Evidence of an Association Between the Vasopressin V1b Receptor Gene (AVPR1B) and Childhood-Onset Mood Disorders. Archives of General Psychiatry, 2007, 64, 1189.	13.8	74
444	Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. Journal of Psychopharmacology, 2007, 21, 718-727.	2.0	41
445	The gene for synapsin III and attention-deficit hyperactivity disorder. Psychiatric Genetics, 2007, 17, 109-112.	0.6	7
446	Monoamine oxidase A gene is associated with borderline personality disorder. Psychiatric Genetics, 2007, 17, 153-157.	0.6	68
447	GPR50 is not associated with childhood-onset mood disorders in a large sample of Hungarian families. Psychiatric Genetics, 2007, 17, 347-350.	0.6	7
448	Serotonin system genes and childhood-onset aggression. Psychiatric Genetics, 2007, 17, 11.	0.6	12
449	Association study of the brain-derived neurotrophic factor gene and childhood aggression. Psychiatric Genetics, 2007, 17, 7-8.	0.6	3
450	Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. International Journal of Neuropsychopharmacology, 2007, 10, 639-51.	1.0	64

#	Article	IF	CITATIONS
451	Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. International Journal of Neuropsychopharmacology, 2007, 10, 697-704.	1.0	105
452	CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited. Pharmacogenetics and Genomics, 2007, 17, 339-347.	0.7	39
453	Parent-of-origin effect and genomic imprinting of the HTR2A receptor gene T102C polymorphism in psychosis. Psychiatry Research, 2007, 151, 243-248.	1.7	14
454	Association study between the corticotropin-releasing hormone receptor 2 gene and suicidality in bipolar disorder. European Psychiatry, 2007, 22, 282-287.	0.1	57
455	Molecular analysis of a chromosome 4 inversion segregating in a large schizophrenia kindred from Hong Kong. Schizophrenia Research, 2007, 95, 228-235.	1.1	1
456	Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study. Biological Psychiatry, 2007, 62, 327-331.	0.7	186
457	Further evidence of MAO-A gene variants associated with bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 37-40.	1.1	17
458	The serotonin receptor HTR1B: Gene polymorphisms in attention deficit hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 121-125.	1.1	22
459	Sequence variants within exon 1 of MECP2 occur in females with mental retardation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 355-360.	1.1	21
460	Association study of the brainâ€derived neurotropic factor (BDNF) gene in attention deficit hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 976-981.	1.1	30
461	Haplotype association study betweenDRD1 gene and bipolar type I affective disorder in two samples from Canada and Sardinia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 237-241.	1.1	13
462	Differential expression and parent-of-origin effect of the 5-HT2A receptor gene C102T polymorphism: Analysis of suicidality in schizophrenia and bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 370-374.	1.1	32
463	HTR2C haplotypes and antipsychoticsâ€induced weight gain: Xâ€linked multimarker analysis. Human Psychopharmacology, 2007, 22, 463-467.	0.7	39
464	No preferential transmission of paternal alleles at risk genes in attention-deficit hyperactivity disorder. Molecular Psychiatry, 2007, 12, 226-229.	4.1	29
465	Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Molecular Psychiatry, 2007, 12, 794-795.	4.1	78
466	Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry, 2007, 12, 1058-1060.	4.1	16
467	Use of Streamflow Data to Estimate Base Flow/Groundâ€Water Recharge For Wisconsin ¹ . Journal of the American Water Resources Association, 2007, 43, 220-236.	1.0	38
468	Brain-derived neurotrophic factor (BDNF) gene not associated with antidepressant-induced mania. Bipolar Disorders, 2007, 9, 521-525.	1.1	22

#	Article	IF	CITATIONS
469	Association of the glutamate receptor subunit geneGRIN2Bwith attention-deficit/hyperactivity disorder. Genes, Brain and Behavior, 2007, 6, 444-452.	1.1	101
470	Association study of the nicotinic acetylcholine receptor ?4 subunit gene, CHRNA4, in attention-deficit hyperactivity disorder. Genes, Brain and Behavior, 2007, 7, 070514070132001-???.	1.1	22
471	Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia. NeuroMolecular Medicine, 2007, 9, 169-177.	1.8	47
472	Dopamine Genes and Pathological Gambling in Discordant Sib-Pairs. Journal of Gambling Studies, 2007, 23, 421-433.	1.1	111
473	Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia. NeuroMolecular Medicine, 2007, 9, 169-177.	1.8	2
474	Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. Journal of Psychiatry and Neuroscience, 2007, 32, 412-6.	1.4	32
475	Serotonin Transporter Promoter Gain-of-Function Genotypes Are Linked to Obsessive-Compulsive Disorder. American Journal of Human Genetics, 2006, 78, 815-826.	2.6	1,032
476	The serotonin- $10\hat{l}^2$ receptor gene and severity of obsessive-compulsive disorder in women with bulimia nervosa. European Neuropsychopharmacology, 2006, 16, 1-6.	0.3	22
477	Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. European Neuropsychopharmacology, 2006, 16, 248-259.	0.3	39
478	Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia. European Neuropsychopharmacology, 2006, 16, 268-271.	0.3	32
479	N-methyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophrenia Research, 2006, 84, 214-221.	1.1	115
480	Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics, 2006, 7, 863-887.	0.6	139
481	Serotonin 2A receptor gene is associated with personality traits, but not to disorder, in patients with borderline personality disorder. Neuroscience Letters, 2006, 408, 214-219.	1.0	52
482	Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Research, 2006, 141, 123-128.	1.7	27
483	Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder. British Journal of Psychiatry, 2006, 189, 317-323.	1.7	101
484	Gene expression of tryptophan hydroxylase 2 in post-mortem brain of suicide subjects. International Journal of Neuropsychopharmacology, 2006, 9, 21.	1.0	22
485	Catechol-O-methyltransferase and Monoamine Oxidase-A Polymorphisms and Treatment Response to Typical and Atypical Neuroleptics. Journal of Clinical Psychopharmacology, 2006, 26, 338-340.	0.7	5
486	The Dopamine D4 Receptor Gene and Moderation of the Association Between Externalizing Behavior and IQ. Archives of General Psychiatry, 2006, 63, 1410-6.	13.8	53

#	Article	IF	CITATIONS
487	Serotonin Transporter Polymorphisms and Persistent, Pervasive Childhood Aggression. American Journal of Psychiatry, 2006, 163, 1103-1105.	4.0	137
488	Lack of association between the corticotrophin-releasing hormone receptor 2 gene and panic disorder. Psychiatric Genetics, 2006, 16, 93-97.	0.6	20
489	Tumor necrosis factor-alpha gene is not associated with obsessive-compulsive disorder. Psychiatric Genetics, 2006, 16, 43-45.	0.6	9
490	The Genetics of Gambling and Behavioral Addictions. CNS Spectrums, 2006, 11, 931-939.	0.7	41
491	Regulation of $\hat{l}\pm 7$ -nicotinic receptor subunit and $\hat{l}\pm 7$ -like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatrica Scandinavica, 2006, 114, 211-215.	2,2	47
492	Imaging Phenotypes and Genotypes in Schizophrenia. Neuroinformatics, 2006, 4, 21-50.	1.5	29
493	Association Study Between Functional Polymorphisms in the Cytochrome P450 1A2 and 2D6 Genes and Polydipsia in Schizophrenia. NeuroMolecular Medicine, 2006, 8, 381-388.	1.8	2
494	Family and case–control association study of the tumor necrosis factor-alpha (TNF-α) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology, 2006, 188, 171-182.	1.5	48
495	Genetic interaction between $\hat{l}\pm 4$ and \hat{l}^22 subunits of high affinity nicotinic receptor: analysis in schizophrenia. Experimental Brain Research, 2006, 174, 292-296.	0.7	43
496	Gene–gene interaction between MAOA and COMT in suicidal behavior: Analysis in schizophrenia. Brain Research, 2006, 1097, 26-30.	1.1	42
497	Association between serotonin transporter gene and borderline personality disorder. Journal of Psychiatric Research, 2006, 40, 448-453.	1.5	76
498	Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 36-43.	1.1	81
499	Gene for the serotonin transporter and ADHD: No association with two functional polymorphisms. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 566-570.	1.1	42
500	Association of the Val158Met Catechol O-Methyltransferase Genetic Polymorphism with Panic Disorder. Neuropsychopharmacology, 2006, 31, 2237-2242.	2.8	91
501	A Birth-Season/DRD4 Gene Interaction Predicts Weight Gain and Obesity in Women with Seasonal Affective Disorder: A Seasonal Thrifty Phenotype Hypothesis. Neuropsychopharmacology, 2006, 31, 2498-2503.	2.8	77
502	Glutamate Transporter Gene SLC1A1 Associated With Obsessive-compulsive Disorder. Archives of General Psychiatry, 2006, 63, 769.	13.8	340
503	Association between three functional polymorphisms of the dopamine D2 receptor gene and polydipsia in schizophrenia. International Journal of Neuropsychopharmacology, 2005, 8, 245-253.	1.0	14
504	Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. International Journal of Neuropsychopharmacology, 2005, 8, 411-425.	1.0	109

#	Article	IF	Citations
505	A Linkage Study Between the GABAA \hat{l}^22 and GABAA \hat{l}^32 Subunit Genes and Major Psychoses. CNS Spectrums, 2005, 10, 57-61.	0.7	4
506	No association between brain-derived neurotrophic factor gene and obsessive-compulsive disorder. Psychiatric Genetics, 2005, 15, 235.	0.6	23
507	Brain-derived neurotrophic factor variants are associated with childhood-onset mood disorder: confirmation in a Hungarian sample. Molecular Psychiatry, 2005, 10, 861-867.	4.1	109
508	Association of the calcyon gene (DRD1IP) with attention deficit/hyperactivity disorder. Molecular Psychiatry, 2005, 10, 1117-1125.	4.1	36
509	The interaction between TPH2 promoter haplotypes and clinical-demographic risk factors in suicide victims with major psychoses. Genes, Brain and Behavior, 2005, 5, 107-110.	1.1	26
510	A Cys23–Ser23 substitution in the 5-HT receptor gene influences body weight regulation in females with seasonal affective disorder: An Austrian–Canadian collaborative study. Journal of Psychiatric Research, 2005, 39, 561-567.	1.5	8
511	Association study of neurotrophic tyrosine kinase receptor type 2 (NTRK2) and childhood-onset mood disorders., 2005, 132B, 90-95.		22
512	Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 134B, 25-29.	1.1	55
513	Association study of a novel functional polymorphism of the serotonin transporter gene in bipolar disorder and suicidal behaviour. Psychopharmacology, 2005, 182, 128-131.	1.5	34
514	Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology, 2005, 183, 378-382.	1.5	52
515	Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology, 2005, 181, 179-187.	1.5	90
516	Pharmacogenetics in drug development. Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1579-1588.	1.8	19
517	Investigation of the Relationship of Attention Deficit Hyperactivity Disorder to the EKN1 Gene on Chromosome 15q21. Scientific Studies of Reading, 2005, 9, 261-283.	1.3	13
518	Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia. European Neuropsychopharmacology, 2005, 15, 347-352.	0.3	28
519	Suggestive association between the C825T polymorphism of the G-protein \hat{I}^2 3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. European Neuropsychopharmacology, 2005, 15, 525-531.	0.3	59
520	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neuroscience Letters, 2005, 379, 81-89.	1.0	93
521	Gene–gene interaction between MAOA and COMT in suicidal behavior. Neuroscience Letters, 2005, 383, 151-154.	1.0	36
522	Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. Neuroscience Letters, 2005, 388, 116-120.	1.0	16

#	Article	IF	Citations
523	Human p53 tumor suppressor gene (TP53) and schizophrenia: Case–control and family studies. Neuroscience Letters, 2005, 388, 173-178.	1.0	52
524	Promoter polymorphism of second tryptophan hydroxylase isoform (TPH2) in schizophrenia and suicidality. Psychiatry Research, 2005, 134, 195-198.	1.7	45
525	Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. Pharmacological Research, 2005, 51, 381-384.	3.1	8
526	Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. Schizophrenia Research, 2005, 77, 261-270.	1.1	30
527	Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophrenia Research, 2005, 78, 137-146.	1.1	45
528	How does drug abuse interact with familial and developmental factors in the etiology of schizophrenia?., 2004,, 248-270.		2
529	Pharmacogenetics of Psychotropic Drug Response. American Journal of Psychiatry, 2004, 161, 780-796.	4.0	286
530	Evidence of Association between Smoking and α7 Nicotinic Receptor Subunit Gene in Schizophrenia Patients. Neuropsychopharmacology, 2004, 29, 1522-1526.	2.8	129
531	Linkage of M5 Muscarinic and α7-Nicotinic Receptor Genes on 15q13 to Schizophrenia. Neuropsychobiology, 2004, 50, 124-127.	0.9	62
532	Replication Test for Association of the IL-1 Receptor Antagonist Gene, IL1RN, with Attention-Deficit/Hyperactivity Disorder. Neuropsychobiology, 2004, 50, 231-234.	0.9	25
533	Decisionâ€Making Deficits and Overeating: A Risk Model for Obesity. Obesity, 2004, 12, 929-935.	4.0	166
534	Genetic Association Analysis of Neuronal Nitric Oxide Synthase Gene Polymorphism With Tardive Dyskinesia. NeuroMolecular Medicine, 2004, 5, 163-170.	1.8	21
535	Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology, 2004, 174, 530-8.	1.5	179
536	No evidence of linkage or association between the norepinephrine transporter (NET) geneMnll polymorphism and adult ADHD. American Journal of Medical Genetics Part A, 2004, 124B, 38-40.	2.4	31
537	No evidence of association or linkage disequilibrium between polymorphisms in the 5′ upstream and coding regions of the dopamine D4 receptor gene and schizophrenia in a Portuguese population. , 2004, 125B, 20-24.		8
538	COMT158 polymorphism and hostility. American Journal of Medical Genetics Part A, 2004, 127B, 28-29.	2.4	28
539	Adrenergic alpha 2C receptor genomic organization: Association study in adult ADHD. American Journal of Medical Genetics Part A, 2004, 127B, 65-67.	2.4	22
540	Myelin oligodendrocyte glycoprotein (MOG) gene is associated with obsessive-compulsive disorder. American Journal of Medical Genetics Part A, 2004, 129B, 64-68.	2.4	65

#	Article	IF	CITATIONS
541	No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia. Schizophrenia Research, 2004, 69, 301-305.	1.1	27
542	Association between schizophrenia and the syntaxin 1A gene. Biological Psychiatry, 2004, 56, 24-29.	0.7	38
543	The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: An evolutionary perspective. Biological Psychiatry, 2004, 56, 665-669.	0.7	94
544	Pharmacogenetics of antipsychotic-induced weight gain. Pharmacological Research, 2004, 49, 309-329.	3.1	69
545	Family association study between DRD2 and DRD3 gene polymorphisms and schizophrenia in a Portuguese population. Psychiatry Research, 2004, 125, 185-191.	1.7	16
546	NOTCH4 gene haplotype is associated with schizophrenia in African Americans. Biological Psychiatry, 2004, 55, 112-117.	0.7	27
547	Nonparametric Linkage Analysis Between Schizophrenia and Candidate Genes of Dopaminergic and Serotonergic Systems. CNS Spectrums, 2004, 9, 302-308.	0.7	0
548	Linkage disequilibrium analysis of the dopamine beta-hydroxylase gene in persistent attention deficit hyperactivity disorder. Psychiatric Genetics, 2004, 14, 117-120.	0.6	22
549	Association of the serotonin transporter and $5 \text{HT} 10^2$ receptor genes with extreme, persistent and pervasive aggressive behaviour in children. Psychiatric Genetics, 2004, 14, 143-146.	0.6	79
550	Polymorphisms in glutamate decarboxylase genes: analysis in schizophrenia. Psychiatric Genetics, 2004, 14, 39-42.	0.6	21
551	No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia. Psychiatric Genetics, 2004, 14, 177-180.	0.6	14
552	Brain development in healthy children and adolescents: magnetic resonance imaging studies. , 2004, , 35-44.		9
553	Cognitive development in adolescence: cerebral underpinnings, neural trajectories, and the impact of aberrations., 2004,, 69-88.		12
554	Can structural magnetic resonance imaging provide an alternative phenotype for genetic studies of schizophrenia?., 2004, , 138-155.		1
555	Schizophrenia, neurodevelopment, and epigenetics. , 2004, , 174-190.		6
556	Early environmental risk factors for schizophrenia. , 2004, , 191-209.		3
557	Is there a role for social factors in a comprehensive development model for schizophrenia?., 2004,, 224-247.		2
558	Developmental dysregulation of the dopamine system and the pathophysiology of schizophrenia., 2004,, 273-294.		17

#	Article	IF	CITATIONS
559	The development of "mis-wired―limbic lobe circuitry in schizophrenia and bipolar disorder. , 2004, , 295-309.		3
560	Premorbid structural abnormalities in schizophrenia., 2004,, 347-372.		8
561	Does disordered brain development occur across diagnostic boundaries?. , 2004, , 390-412.		1
562	Developmental models and hypothesis-driven early interventions in schizophrenia., 2004,, 455-472.		1
563	Velo-cardio-facial syndrome (deletion 22q11.2): a homogeneous neurodevelopmental model for schizophrenia., 2004,, 121-137.		4
564	Nutritional factors and schizophrenia. , 2004, , 156-173.		0
565	Can one identify preschizophrenia children?. , 2004, , 415-431.		0
566	Do degenerative changes operate across diagnostic boundaries? The case for glucocorticoid involvement in major psychiatric disorders., 2004, , 111-120.		0
567	Brain plasticity and long-term function after early cerebral insult: the example of very preterm birth. , 2004, , 89-108.		2
568	Neurodegenerative models of schizophrenia., 2004,, 373-389.		1
569	Cognitive development: functional magnetic resonance imaging studies. , 2004, , 45-68.		3
570	Transcriptomes in schizophrenia: assessing altered gene expression with microarrays., 2004,, 210-223.		0
571	High-risk studies, brain development, and schizophrenia. , 2004, , 432-454.		0
572	Genes and brain development. , 2004, , 3-34.		0
573	Development of thalamocortical circuitry and the pathophysiology of schizophrenia., 2004, , 310-329.		0
574	X chromosome, estrogen, and brain development: implications for schizophrenia., 2004,, 330-346.		2
575	The Serotonin Transporter Gene in Aggressive Children with and without ADHD and Nonaggressive Matched Controls. Annals of the New York Academy of Sciences, 2003, 1008, 248-251.	1.8	60
576	Anticipation and CAG•CTG repeat expansion in schizophrenia and bipolar affective disorder. Current Psychiatry Reports, 2003, 5, 145-154.	2.1	11

#	Article	IF	Citations
577	Early age at onset as a risk factor for poor outcome of bipolar disorder. Journal of Psychiatric Research, 2003, 37, 297-303.	1.5	198
578	Overview: Towards individualized treatment in schizophrenia. Drug Development Research, 2003, 60, 75-94.	1.4	9
579	N-methyl-d-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case-control analyses. American Journal of Medical Genetics Part A, 2003, 119B, 24-27.	2.4	24
580	Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disorders, 2003, 5, 58-61.	1.1	235
581	Discovery of a null mutation in a human trace amine receptor gene. Genomics, 2003, 82, 531-536.	1.3	28
582	The Genetics of Adult-Onset Neuropsychiatric Disease: Complexities and Conundra?. Science, 2003, 302, 822-826.	6.0	160
583	Monozygotic Twins Exhibit Numerous Epigenetic Differences: Clues to Twin Discordance?. Schizophrenia Bulletin, 2003, 29, 169-178.	2.3	285
584	Pharmacogenomics in schizophrenia: the quest for individualized therapy. Human Molecular Genetics, 2002, 11, 2517-2530.	1.4	111
585	Attention Deficit Hyperactivity Disorder and the Gene for Dopamine Beta-Hydroxylase. American Journal of Psychiatry, 2002, 159, 1046-1048.	4.0	48
586	Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia. Biological Psychiatry, 2002, 52, 701-707.	0.7	304
587	Linkage disequilibrium between dopamine D1 receptor gene (DRD1) and bipolar disorder. Biological Psychiatry, 2002, 52, 1144-1150.	0.7	40
588	â^'759C/genetic variation of 5HT2C receptor and clozapine-induced weight gain. Lancet, The, 2002, 360, 1790-1791.	6.3	114
589	The Brain-Derived Neurotrophic Factor Gene Confers Susceptibility to Bipolar Disorder: Evidence from a Family-Based Association Study. American Journal of Human Genetics, 2002, 71, 651-655.	2.6	544
590	Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder. Behavioural Brain Research, 2002, 130, 85-90.	1.2	27
591	A transmission disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder. Behavioural Brain Research, 2002, 130, 91-95.	1.2	38
592	Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia., 2002,, 391-400.		2
593	Pharmacogenetics of Tardive Dyskinesia Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism. Neuropsychopharmacology, 2002, 27, 105-119.	2.8	217
594	99A Quantitative Trait Locus Analysis of the Dopamine Transporter Gene in Adults with ADHD. Neuropsychopharmacology, 2002, 27, 655-62.	2.8	32

#	Article	IF	CITATIONS
595	The norepinephrine transporter gene and attention-deficit hyperactivity disorder. American Journal of Medical Genetics Part A, 2002, 114, 255-259.	2.4	95
596	Family-Based Association Study of the Serotonin-2A Receptor Gene (5-HT2A) and Bipolar Disorder. NeuroMolecular Medicine, 2002, 2, 251-260.	1.8	15
597	A Drosophila Model for Attention Deficit Hyperactivity Disorder (ADHD): No Evidence of Association with PRKG1 Gene. NeuroMolecular Medicine, 2002, 2, 281-288.	1.8	12
598	Lack of association between the Tâ†'C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophrenia Research, 2001, 47, 49-58.	1.1	84
599	Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder. Biological Psychiatry, 2001, 49, 333-339.	0.7	161
600	Altered TRPC7 gene expression in bipolar-I disorder. Biological Psychiatry, 2001, 50, 620-626.	0.7	68
601	Polymorphism of the serotonin 5-HT1B receptor gene (HTR1B) associated with minimum lifetime body mass index in women with bulimia nervosa. Biological Psychiatry, 2001, 50, 640-643.	0.7	51
602	Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. Journal of Proteomics, 2001, 47, 151-157.	2.4	28
603	Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor. Molecular Pharmacology, 2001, 60, 1181-1188.	1.0	553
604	Genetics of Childhood Disorders: XXIII. ADHD, Part 7: The Serotonin System. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 253-256.	0.3	63
605	Dopamine system genes not linked to social phobia. Psychiatric Genetics, 2001, 11, 213-217.	0.6	34
606	CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2001, 21, 398-407.	0.7	71
607	5?-Untranslated region of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. American Journal of Medical Genetics Part A, 2001, 105, 84-90.	2.4	82
608	Evidence for linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. American Journal of Medical Genetics Part A, 2001, 105, 669-674.	2.4	78
609	The $5HT1D\hat{l}^2$ Receptor Gene in Bipolar Disorder A Family-based Association Study. Neuropsychopharmacology, 2001, 25, 608-613.	2.8	22
610	Genes and attention-deficit hyperactivity disorder. Clinical Neuroscience Research, 2001, 1, 207-216.	0.8	71
611	The Role of Serotonin Transporter Protein Gene in Antidepressant-Induced Mania in Bipolar Disorder. Archives of General Psychiatry, 2001, 58, 539.	13.8	178
612	Is the 5-HT1DβReceptor Gene Implicated in the Pathogenesis of Obsessive-Compulsive Disorder?. American Journal of Psychiatry, 2000, 157, 1160-1161.	4.0	95

#	Article	IF	CITATIONS
613	Linkage study of two polymorphisms at the dopamine D3 receptor gene and attention-deficit hyperactivity disorder., 2000, 96, 114-117.		41
614	The unstable trinucleotide repeat story of major psychosis., 2000, 97, 77-97.		53
615	Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. American Journal of Medical Genetics Part A, 2000, 96, 262-267.	2.4	114
616	Adult attention deficit hyperactivity disorder and the dopamine D4 receptor gene. American Journal of Medical Genetics Part A, 2000, 96, 273-277.	2.4	127
617	Detection of expansion regions in Portuguese bipolar families. American Journal of Medical Genetics Part A, 2000, 96, 854-857.	2.4	13
618	Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biological Psychiatry, 2000, 47, 252-266.	0.7	92
619	An Unstable Trinucleotide-Repeat Region on Chromosome 13 Implicated in Spinocerebellar Ataxia: A Common Expansion Locus. American Journal of Human Genetics, 2000, 66, 819-829.	2.6	85
620	Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene. CNS Spectrums, 1999, 4, 30-34, 47-56.	0.7	17
621	Clinical characteristics of bipolar disorder subjects with large CAG/CTG repeat DNA. Journal of Affective Disorders, 1999, 55, 221-224.	2.0	4
622	Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia. Neuropsychopharmacology, 1999, 21, 17-27.	2.8	147
623	Dopamine D4 Receptor Gene Novelty or Nonsense?. Neuropsychopharmacology, 1999, 21, 3-16.	2.8	140
624	Intergenerational CAG repeat expansion at ERDA1 in a family with childhood-onset depression, schizoaffective disorder, and recurrent major depression., 1999, 88, 79-82.		19
625	Linkage study of Catechol-O-Methyltransferase and attention-deficit hyperactivity disorder. , 1999, 88, 710-713.		82
626	DNA methylation at the putative promoter region of the human dopamine D2 receptor gene. NeuroReport, 1999, 10, 1249-1255.	0.6	37
627	Genetic Association Analysis of Serotonin System Genes in Bipolar Affective Disorder. American Journal of Psychiatry, 1999, 156, 136-138.	4.0	81
628	Genetics of Schizophrenia: Current Findings and Issues. CNS Spectrums, 1999, 4, 17-21.	0.7	8
629	Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients. Neuropsychopharmacology, 1998, 19, 123-132.	2.8	220
630	Nonparametric Linkage does not provide strong evidence for linkage to APOE in a large alzheimer's kindred. American Journal of Medical Genetics Part A, 1998, 81, 268-268.	2.4	0

#	Article	IF	CITATIONS
631	Regional brain changes in [3H]SCH 23390 binding to dopamine D1 receptors after long-term haloperidol treatment: lack of correspondence with the development of vacuous chewing movements. Behavioural Brain Research, 1998, 90, 125-132.	1.2	13
632	Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Current Opinion in Neurobiology, 1998, 8, 263-271.	2.0	271
633	Genetic linkage to the serotonin transporter protein and 5HT2A receptor genes excluded in generalized social phobia. Psychiatry Research, 1998, 81, 283-291.	1.7	64
634	Genetic anticipation: fact or artifact, genetics or epigenetics?. Lancet, The, 1997, 350, 1403-1404.	6.3	16
635	Selection of homogeneous populations for genetic study: The Portugal genetics of psychosis project. American Journal of Medical Genetics Part A, 1997, 74, 286-288.	2.4	35
636	Absence of linkage for schizophrenia on the short arm of chromosome 5 in multiplex Canadian families. American Journal of Medical Genetics Part A, 1997, 74, 472-474.	2.4	13
637	Localized changes in GABA receptor-gated chloride channel in rat brain after long-term haloperidol: Relation to vacuous chewing movements., 1997, 25, 73-79.		19
638	Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophrenia Research, 1996, 21, 111-116.	1.1	72
639	Psychosis and genes with trinucleotide repeat polymorphism. Human Genetics, 1996, 97, 244-246.	1.8	30
640	Autoradiographic mapping of $\hat{l}\frac{1}{4}$ opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements. Psychopharmacology, 1996, 128, 97-104.	1.5	28
641	Direct detection of expanded trinucleotide repeats using PCR and DNA hybridization techniques. , 1996, 67, 85-91.		20
642	No evidence for association of dopamine D2 receptor variant (Ser $311/\text{Cys}311$) with major psychosis., 1996, 67, 415-417.		34
643	Localization of the Darier Disease Gene to a 2-cM Portion of 12q23-24.1. Journal of Investigative Dermatology, 1996, 106, 365-367.	0.3	24
644	Association study between the dopamine D4 receptor gene and schizophrenia. American Journal of Medical Genetics Part A, 1995, 60, 452-455.	2.4	49
645	Association study of dopamine D3 receptor gene and schizophrenia. American Journal of Medical Genetics Part A, 1995, 60, 558-562.	2.4	52
646	Genetics of psychosis. Current Opinion in Psychiatry, 1995, 8, 25-28.	3.1	0
647	Genetic linkage evaluation of twenty-four loci in an eastern Canadian family segregating Darier's disease (keratosis follicularis). Journal of the American Academy of Dermatology, 1994, 31, 27-30.	0.6	7
648	An Association Study between Schizophrenia and the Dopamine Receptor Genes DRD3 and DRD4 Using Haplotype Relative Risk. Human Heredity, 1994, 44, 328-336.	0.4	47

#	Article	IF	CITATIONS
649	Review of the putative association of dopamine D2 receptor and alcoholism: A meta-analysis. American Journal of Medical Genetics Part A, 1993, 48, 78-82.	2.4	125
650	A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Human Molecular Genetics, 1993, 2, 767-773.	1.4	524
651	An Alu sequence interupts a human 5-hydroxytryptamine1D receptor pseudogene. Gene, 1993, 124, 295-301.	1.0	20
652	A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene, 1993, 136, 355-360.	1.0	731
653	Identification of a processed pseudogene related to the functional gene encoding the GM2 activator protein: Localization of the pseudogene to human chromosome 3 and the functional gene to human chromosome 5. Genomics, 1992, 14, 796-798.	1.3	22
654	Echoes of D4 receptor repeats. Nature, 1992, 360, 424-424.	13.7	9
655	Human dopamine D5 receptor pseudogenes. Gene, 1991, 109, 211-218.	1.0	53
656	Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature, 1990, 347, 80-83.	13.7	470
657	Genetic and physical mapping and population studies of a fibronectin receptor \hat{l}^2 -subunit-like sequence on human chromosome 19. Genomics, 1990, 8, 340-346.	1.3	8
658	Evidence against linkage of schizophrenia to markers on chromosome 5 in a northern Swedish pedigree. Nature, 1988, 336, 167-170.	13.7	405
659	Systematic review of mitochondrial genetic variation in attention-deficit/hyperactivity disorder. European Child and Adolescent Psychiatry, 0, , .	2.8	2